Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND

Enveric Biosciences, Inc.

Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.
Cash $4.7M at Dec 31; raised $12.2M in gross proceeds during FY 2025; subsequently raised $1.5M (Jan 2026) and $1.45M (Feb 2026).
EB-003 showed positive preclinical results in chronic depression and PTSD models; preparing IND submission to FDA for first-in-human trial.
PGR petition by Gilgamesh/AbbVie against Enveric patent withdrawn; patent covers bretisilocin (GM-2505) acquired by AbbVie for $1.2B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.